DerekWelsbie
MD, PhD
Location
La Jolla, CA, USA
Current Organization
University of California, San Diego
Biography
Dr. Welsbie is an assistant professor of ophthalmology at the Shiley Eye Institute of the University of California, San Diego. He has an active medical and surgical practice, specializing in the care of glaucoma patients. He completed his medical and graduate training at the University of California, Los Angeles and his residency and glaucoma fellowship training at the Wilmer Eye Institute of the Johns Hopkins University School of Medicine.
Dr. Welsbie’s laboratory focuses on the development of neuroprotective agents as a novel treatment strategy for glaucoma. Specifically, he uses high-throughput genetic screening to identify genes involved in the degeneration of retinal ganglion cells (RGCs), the nerve cells whose death defines glaucoma. Once these target genes are identified, he then uses a combination of gene therapy- and medication-based approaches to block the function of these genes and potentially halt the disease.
Grants
Grants Featuring
Derek Welsbie, MD, PhD
National Glaucoma Research
Developing Dual Leucine Zipper Kinase Inhibitors for Glaucoma
Active Dates
July 01, 2014 - June 30, 2016
Principal Investigator
Derek Welsbie, MD, PhD
Developing Dual Leucine Zipper Kinase Inhibitors for Glaucoma
Active Dates
July 01, 2014 - June 30, 2016
Principal Investigator
Derek Welsbie, MD, PhD
National Glaucoma Research
Genome-Wide RNAi Screening in Retinal Ganglion Cells
Active Dates
July 01, 2012 - August 30, 2012
Principal Investigator
Derek Welsbie, MD, PhD
Genome-Wide RNAi Screening in Retinal Ganglion Cells
Active Dates
July 01, 2012 - August 30, 2012
Principal Investigator
Derek Welsbie, MD, PhD
National Glaucoma Research
Cerebrospinal Fluid Pressure at the Link Between Glaucoma and Alzheimer's Disease
Active Dates
July 01, 2012 - June 30, 2014
Principal Investigator
Peter De Deyn, MD, PhD
Cerebrospinal Fluid Pressure at the Link Between Glaucoma and Alzheimer's Disease
Active Dates
July 01, 2012 - June 30, 2014
Principal Investigator
Peter De Deyn, MD, PhD